Digital Therapeutic Against Migraine Closes New Financing Round
2021 has been a year of accomplishment for the Berlin-based startup Newsenselab
Berlin Startup Newsenselab is rounding out a year of successes with their most recent financing round. Headlining the list of achievements is “M-sense Migräne”, a digital health application (DiGA) eligible to be reimbursed by statutory health insurances in Germany. With the results of a randomised controlled trial the company is now aiming to prove the effectiveness of the migraine app. With these milestones reached, both existing and new investors participated enthusiastically in the financing round.
Symbolic image
pixabay.com
2021 has been a year of accomplishment for the Berlin-based startup Newsenselab GmbH. Their migraine app has completed its first year on the preliminary listing in the register of certified digital health apps, overseen by the German Federal Institute for Drugs and Medical Devices (BfArM). The results are more than encouraging: not only is Newsenselab drawing a positive balance, but the startup can observe its impact on the medical treatment of migraines overall.
The digital health app “M-sense Migräne” has helped its users to manage over 100,000 headache attacks throughout the past year. Physicians trust the app’s functions to support them in their treatment of migraine patients and prescribe the digital health app with increasing frequency.
Seeking to fully prove the effectiveness of their digital health app, Newsenselab conducted the digital, decentralised RCT-trial EMMA this year as well. EMMA was the first clinical study on migraine to be conducted exclusively online, and sets the standard for digital clinical trials and digitized recruitment strategies. As of now, EMMA saw its last patient-out on December 6, and an independent scientific institution is now transitioning from the completion of the clinical evaluation to readying the publication of the results, which are to be expected early in 2022.
Newsenselab is thrilled to add to this successful year by announcing the closing of their most recent financing round. The round was led by Berlin’s IBB Ventures, Dutch impact investor Noaber and Munich based MedTech Entrepreneurs with participation of High-Tech Gründerfonds, Eternity.Health and business angel Dr. Klaus Hilleke. Law firm Dentons advised the company.
"The M-sense product empowers patients to better manage their migraines and leads to a series of incremental improvements in their quality of life. The team showed resilience while navigating the turbulent developments in the emerging field of prescription digital therapeutics and has managed to set the standard for digital clinical trials. This combination of healthspan improvement and operational excellence is exactly what we’re looking for at Noaber", Thijs Schaap, investment manager at Noaber.
"MedTech Entrepreneurs (MTE) are very excited to support Newsenselab on their journey towards improving lives of chronically ill patients starting with 9 million people suffering from migraine every day in Germany. Newsenselab with their strong team and excellent digital technology perfectly strengthens our portfolio", Dominik Moll, Managing Partner of MTE.
Newsenselab is excited to use this latest financing round to expand on its expertise in creating digital medicine for episodic chronic diseases.
"We are very happy about the trust and support that our existing and new investors are extending to us. This gives us the chance to develop digital therapeutics for more indications and expand “M-sense Migräne” in Germany and beyond", Nils Bottler, newly appointed Managing Director of Newsenselab.
"I was delighted with the addition of Nils to our senior management team and the new push from investors. Newsenselab is now another crucial step closer to our vision of making medicine precise", Dr. rer. nat. Markus Dahlem, Managing Director of Newsenselab.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
